VBI VACCINES INC (VBIV) Stock Price, Forecast & Analysis
USA - NASDAQ:VBIV - CA91822J2020 - Common Stock
VBIV Key Statistics, Chart & Performance
The current stock price of VBIV is 0.0653 USD. In the past month the price decreased by -91.32%. In the past year, price decreased by -94.82%.
VBIV Latest News, Press Relases and Analysis
VBIV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.86 | 381.54B | ||
| AMGN | AMGEN INC | 13.56 | 159.24B | ||
| GILD | GILEAD SCIENCES INC | 14.72 | 149.58B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.1 | 109.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.28 | 68.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 877.36 | 58.65B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 51.00B | ||
| INSM | INSMED INC | N/A | 38.74B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.06 | 34.42B | ||
| NTRA | NATERA INC | N/A | 27.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.94B | ||
| BIIB | BIOGEN INC | 9.18 | 22.53B |
Related stock screener links
About VBIV
Company Profile
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2001-11-19. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Company Info
VBI VACCINES INC
160 Second Street, Cambridge
Cambridge MASSACHUSETTS 02142 US
CEO: Jeffrey Baxter
Employees: 131
Phone: 16178303031
VBI VACCINES INC / VBIV FAQ
Can you describe the business of VBI VACCINES INC?
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2001-11-19. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
What is the current price of VBIV stock?
The current stock price of VBIV is 0.0653 USD. The price decreased by -50.87% in the last trading session.
Does VBI VACCINES INC pay dividends?
VBIV does not pay a dividend.
How is the ChartMill rating for VBI VACCINES INC?
VBIV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting VBIV stock to perform?
7 analysts have analysed VBIV and the average price target is 5.1 USD. This implies a price increase of 7710.11% is expected in the next year compared to the current price of 0.0653.
Would investing in VBI VACCINES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VBIV.
VBIV Technical Analysis
VBIV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VBIV. VBIV has a bad profitability rating. Also its financial health evaluation is rather negative.
VBIV Financial Highlights
Over the last trailing twelve months VBIV reported a non-GAAP Earnings per Share(EPS) of -6.8. The EPS decreased by -90.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VBIV Forecast & Estimates
7 analysts have analysed VBIV and the average price target is 5.1 USD. This implies a price increase of 7710.11% is expected in the next year compared to the current price of 0.0653.
For the next year, analysts expect an EPS growth of 86.5% and a revenue growth -2.62% for VBIV